S.H. Park

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆

S.H. Park, D.H. Lim, Tae Sung Sohn et al. · Annals of Oncology · 2020 · 272 citations · Full text

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 69 citations · Full text

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +7

Ongoing Evolution of DRAM Scaling via Third Dimension -Vertically Stacked DRAM -

Ji Won Han, S.H. Park, Moonyoung Jeong et al. · 2023 · 60 citations

Third Dimension, Bit Density, Electrical Engineering +15

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Enrique Grande, Matt D. Galsky, J.Á. Arranz Arija et al. · Annals of Oncology · 2019 · 39 citations · Full text

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +8

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

Thomas Powles, Michiel S. van der Heijden, D. Castellano Gauna et al. · Annals of Oncology · 2020 · 20 citations

Care Chemotherapy, Urology, Urologic Cancer Epidemiology +9